Bayer Covenants Not To Sue, Still Has Headache - Patent

Bayer's ‘053 patent on its drug Xarelto® expires in November 2024, and Bayer granted Mylan a covenant not to sue. Bayer has a second patent that is subject to a pediatric exclusivity that expires later.

Related Keywords

Caraco Pharm , ,Judge Hatcher ,Orange Book Listed ,Federal Circuit ,Mondaq ,Bayer Covenants Not To Sue ,Till Has Headache ,Intellectual Property ,Patent ,